Seroatlas · Human Serome Atlas

CD79A

B-cell antigen receptor complex-associated protein alpha chain

Also known as: CD79A_HUMAN, Ig-alpha, IGA, IGAlpha, MB-1, MB1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P11912
Gene
CD79A
Ensembl
ENSG00000105369
Chromosome
19
Canonical length
226 aa
Protein class
Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-alpha protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

226 residues, UniProt reviewed canonical sequence.

>P11912|CD79A
     1  MPGGPGVLQA LPATIFLLFL LSAVYLGPGC QALWMHKVPA SLMVSLGEDA HFQCPHNSSN
    61  NANVTWWRVL HGNYTWPPEF LGPGEDPNGT LIIQNVNKSH GGIYVCRVQE GNESYQQSCG
   121  TYLRVRQPPP RPFLDMGEGT KNRIITAEGI ILLFCAVVPG TLLLFRKRWQ NEKLGLDAGD
   181  EYEDENLYEG LNLDDCSMYE DISRGLQGTY QDVGSLNIGD VQLEKP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CD79A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.49
Highest tissue expression
510 nTPM

Expression across tissuesHPA

Tissue

  • tonsil: 510 nTPM
  • lymph node: 450 nTPM
  • spleen: 306 nTPM
  • appendix: 201 nTPM
  • small intestine: 158 nTPM
  • thymus: 87 nTPM

Single-cell type

  • plasma cells: 687 nCPM
  • b-cells: 684 nCPM
  • gastric chief cells: 51 nCPM
  • thymocytes: 42 nCPM
  • foveolar cells: 31 nCPM
  • parietal cells: 30 nCPM

Immune cell

  • naive B-cell: 1,463 nTPM
  • memory B-cell: 1,278 nTPM
  • total PBMC: 63 nTPM
  • plasmacytoid DC: 36 nTPM
  • naive CD8 T-cell: 26 nTPM
  • basophil: 13 nTPM

Brain region

  • spinal cord: 1.2 nTPM
  • medulla oblongata: 0.5 nTPM
  • amygdala: 0.4 nTPM
  • basal ganglia: 0.4 nTPM
  • midbrain: 0.4 nTPM
  • pons: 0.4 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CD79A.

Disease | AllUniProt

Conditions CD79A is implicated in, by any mechanism.

Disease | GeneticClinVar

8 pathogenic / likely-pathogenic of 185 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.5
gnomAD pLI
0.69
gnomAD missense Z
1.13
DepMap mean gene effect
0.14
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CD79A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CD79A as an antibody target. Whether an autoantibody or antibody against CD79A could matter depends on whether native CD79A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CD79A is annotated at the cell surface, where native CD79A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CD79A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CD79A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...